Inclisiran in advanced chronic kidney disease (stage G4–G5 non-dialysis): sustained LDL-C reduction and favorable safety profile at 1-year follow-up in a real-world case series - Takeaways - MDSpire

Inclisiran in advanced chronic kidney disease (stage G4–G5 non-dialysis): sustained LDL-C reduction and favorable safety profile at 1-year follow-up in a real-world case series

  • By

  • Avinash Chandu Nanwani

  • Jose Carlos De la Flor Merino

  • Elena Jiménez Mayor

  • Juan Daniel Díaz García

  • Celia Rodríguez Tudero

  • Arturo Villalobos Navarro

  • Esperanza Moral Berrio

  • Adriana Puente García

  • Jesus Hernández Vaquero

  • June 22, 2026

  • 0 min

Share

  • 1

    Inclisiran significantly reduced LDL-C levels from 131.6 mg/dl to 46.1 mg/dl in patients with advanced CKD over one year.

  • 2

    80% of patients achieved LDL-C levels below 70 mg/dl, and 60% reached levels below 55 mg/dl after treatment with inclisiran.

  • 3

    Renal function remained stable with an eGFR change from 22.7 to 23.7 ml/min/1.73 m2 during the study period.

  • 4

    A 27.4% reduction in median albuminuria was noted, although this finding should not be attributed solely to inclisiran.

  • 5

    No adverse events or major cardiovascular events were reported in the cohort during the one-year follow-up.

Original Source(s)

Inclisiran in advanced chronic kidney disease (stage G4–G5 non-dialysis): sustained LDL-C reduction and favorable safety profile at 1-year follow-up in a real-world case series

  • by Avinash Chandu Nanwani, Jose Carlos De la Flor Merino, Elena Jiménez Mayor, Juan Daniel Díaz García, Celia Rodríguez Tudero, Arturo Villalobos Navarro, Esperanza Moral Berrio, Adriana Puente García, Jesus Hernández Vaquero

  • June 22, 2026

Related Content

FDA Cites Manufacturing Issues for Cytisinicline

Application supported by Phase 3 smoking-cessation data and long-term safety findings.

Early aortic valve intervention versus clinical surveillance in patients with asymptomatic severe aortic stenosis: a systematic review and meta-analysis

Pulse pressure and cardiometabolic disease progression: associations with incident multimorbidity and mortality in UK biobank